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Angiotensin converting enzyme inhibitor modulates glomerular
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Angiotensin converting enzyme inhibitor modulates glomerular func-
tion and structure by distinct mechanisms. Rats with puromycin amino-
nucleoside (PAN) nephrosis were given either angiotensin I converting
enzyme inhibitor (ACEI), angiotensin II type I receptor antagonist(Ang IIRA), or no treatment for four weeks and were then monitored
for an additional 12 weeks. In untreated PAN rats, proteinuna reached
a maximum at two weeks (271 38 mg/day). Proteinuria in this early
phase was markedly attenuated by ACE! (96 35 mg/day, P < 0.01),
but unaffected by Ang IIRA (306 34 mg/day). Acute administration of
a bradykinin antagonist substantially dampened the antiproteinuric
effect of ACE! in PAN rats, resulting in an average increase in
proteinuria of4l 14% in ACE!-treated rats (P < 0.05, ACE! vs. ACE!
+ bradykinin antagonist). Acute phase therapy for four weeks with
ACE! or Aug !!RA did not attenuate subsequent glomerulosclerosis.
Separate groups of PAN rats with similar degree of glomeruloscierosis,
assessed at 16 weeks after PAN by renal biopsy, were then treated as
follows: ACE! [50 mg/liter drinking water (DW), or 200 mg/liter DWI,
Ang !IRA (20 mg/liter DW, or 80 mg/liter DW) or no treatment, starting
after renal biopsy. Whereas glomeruloscierosis increased from biopsy
to autopsy at 28 weeks with emergence of low grade proteinuna in
untreated PAN rats, proteinuria was absent and glomerulosclerosis was
ameliorated or reversed in ACE! and Ang !!RA groups. The results
indicate that the early phase proteinuria of PAN nephropathy is
independent of Ang II, and that the antiproteinuric effect of ACE! is, at
least in part, channeled through activation of bradykinin, whereas the
subsequent progression of glomeruloscierosis is caused by a mechanism
involving endogenous Ang !! actions. The results also indicate that the
therapeutic effect of a treatment on glomeruloscierosis cannot be
predicted from its earliest effects on proteinuria.
initially structurally normal with subsequent adaptive responses
of glomerular growth, glomerular hypertension and hyperfiltra-
tion [9, 10] preceding the development of glomerulosclerosis.
Intravenous injection of PAN causes rats to develop massive
proteinuria and glomerular lesions that are ultrastructurally and
biochemically identical to those of human minimal change
disease. The initial nephrotic syndrome then abates spontane-
ously and proteinuria virtually disappears. However, without
additional PAN administration, proteinuria recurs and glomer-
ular lesions develop which have a remarkable resemblance to
the mesangial expansion and glomerulosclerosis seen in a
variety of human chronic renal diseases [7, 8]. As in the
remnant model, ACE! is effective in attenuating the progressive
deterioration of glomerular architecture in the PAN model [7,
81.
Thus, we postulated that treatment with Aug IIRA in this
model would test the pathogenic importance of endogenous
Aug II in a setting of progressive glomerular damage relevant to
human disease. In addition, this study clarified some unre-
solved issues, namely whether the proteinuria-reducing effect
of a therapeutic measure, that is, ACE!, represents its capacity
to protect kidneys from progressive structural damage.
Methods
Experimental groups
Recently, we and others reported that not only angiotensin I
converting enzyme inhibitor (ACE!) [1—4], but also specific
angiotensin II type 1 receptor antagonist (Ang IIRA) [5, 6] is
highly effective in ameliorating the progression of glomerulo-
sclerosis in a remnant kidney model. The results established a
role for endogenous angiotensin II in the pathogenic process of
glomerular sclerosis in this model [5, 6]. In the present study,
we investigated the puromycin aminonucleoside (PAN) nephro-
sis model, which more closely resembles human chronic renal
diseases [7, 8]. Initial nephron number is normal and injury is
diffuse in this model, in marked contrast to the renal ablation
model characterized by a reduced number of nephrons that are
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All experiments were performed on adult male Munich-
Wistar rats weighing 180 to 240 g. Body weights were not
different among groups at the beginning of the experiment. The
rats had free access to standard rat chow and tap water.
Acute nephrotic phase
Under sodium pentobarbital (Nembutal, 30 mg/kg body wt)
anesthesia, the right jugular vein was cannulated and injected
with 42 mg/kg body wt puromycin aminonucleoside (PAN;
Sigma Chemical Co., St. Louis, Missouri, USA) dissolved in 3
ml of saline, given as a single injection over five minutes [8].
After recovery, rats were divided into specific treatment
groups. Group I (PAN control, N = 10) received no therapy.
Group 2 (PAN + ACE!, N = 9) was treated with angiotensin!
converting enzyme inhibitor (ACE!, enalapril maleate, Merck
Research Laboratories, Rahway, New Jersey, USA, "high
dose" 200 mg/liter drinking water, DW) for the first four weeks
after PAN injection (defined as acute nephrotic phase). Group 3
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(PAN + Ang IIRA, N = 7) was treated with angiotensin II
receptor antagonist (Ang IIRA, L-158,809, Merck, "high dose"
80 mg/liter DW) for the first four weeks. The Ang IIRA used is
a new angiotensin II type I receptor antagonist which shows
high affinity and selectivity for the type 1 receptor with no
agonist activity. The drug is orally active and with long-lasting
effects, over six hours after a single dose in the rat [11—13].
These doses were four times the minimum required for control
of systemic blood pressure in our previous study in the remnant
kidney model [5]. In pilot studies, this high dose of ACEI, in
contrast to minimum antihypertensive dose (N =3, 50 mg/liter
DW), was found to ameliorate proteinuria in the acute phase.
After four weeks, all three groups were monitored without
further treatment for an additional 12 weeks. At 2, 8 and 16
weeks, all rats were housed in metabolic cages to obtain
24-hour urine collections. All rats were sacrificed at 16 weeks
after PAN to examine renal morphology.
To explore a possible role of bradykinin in ACEI effects on
proteinuria, a separate group of rats treated with PAN (N =8)
or PAN + ACEI (N = 8) for two weeks were anesthetized and
studied before and after acute treatment with a bradykinin
antagonist, Hoe 140 (0.1 mg/kg body wt, simultaneous single
i.v. and single s.c. doses, Hoechst, Frankfurt, Germany). This
dose of bradykinin antagonist has previously been shown to be
highly specific in viva, completely preventing systemic hypo-
tension in response to exogenous bradykinin after one hour and
with only minimal hypotension (5% decrease in blood pres-
sure) two hours following subcutaneous administration [14].
Whole kidney function (described below) and proteinuria, from
timed collections of urine from catheterized ureters, were
assessed at baseline and one hour after Hoe 140 administration.
Chronic glomerulosclerosis phase
Rats were injected with PAN as above. Three rats did not
show the typical response to PAN injection (urinary protein
excretion < 50 mg/day 2 weeks after PAN) and were excluded
from the study. At 16 weeks, open renal biopsy of the right
kidney was performed under pentobarbital anesthesia via a
midline abdominal incision to assess histologic changes as
previously described [1]. Based on similar levels of renal injury
in the renal biopsy (specified below), rats were grouped and
treatment started within two days of biopsy. Group 4 (PAN
control; N = 10) received no therapy. Group 5 (PAN + ACEI)
was treated with ACEI, either "low dose" (Group 5a; 50
mg/liter DW, N = 8) or "high dose" (Group 5b; 200 mg/liter
DW, N = 8). Group 6 (PAN + Ang IIRA) was treated with Ang
IIRA, either "low dose" (Group 6a; 20 mg/liter DW, N = 7) or
"high dose" (Group 6b; 80 mg/liter DW, N = 8). "Low dose"
was the minimum dose required to decrease systemic blood
pressure in our previous study of remnant kidney model [5].
Group 7 (normal control, N = 7) consisted of age-matched
normal animals that underwent open renal biopsy and were
sacrificed 12 weeks after the biopsy. At 2, 8, 16 and 28 weeks
after PAN injection, all rats were housed individually in meta-
bolic cages to obtain 24-hour collections of urine for determi-
nations of protein, creatinine clearances (16 and 28 weeks) and
urinary electrolytes (28 weeks). Systolic blood pressure was
measured in the conscious state by tail cuff method [151 before
each 24-hour urine collection. Rats were sacrificed at 28 weeks
after assessment of renal function and collection of plasma for
creatinine, electrolytes and triglycerides. Tissues were exam-
ined as described below and morphology was compared be-
tween biopsy and autopsy specimens in the same animals.
Whole kidney function and micropuncture studies for the
chronic phase study
Group 4 to 7 rats were anesthetized with Inactin (Byk,
Gulden Konstanz, Germany; 100 mg/kg body wt, i.p.) at 28
weeks for measurements of kidney function, as previously
described [16]. Briefly, following tracheotomy, indwelling poly-
ethylene catheters (PE-50, Clay Adams, Parsippany, New
Jersey, USA) were placed into the left jugular vein for infusion
of plasma, inulin and para-aminohippurate (PAH) and the left
femoral artery was cannulated to monitor mean systemic arte-
rial pressure (MAP) as previously described [17]. Two consec-
utive timed collections of urine samples were obtained through
ureteral cannulations for determination of urine flow rate, inulin
and PAH concentrations. Arterial blood was collected into
capillary tubes for determinations of plasma inulin and PAH
concentrations at the midpoint of urine collection. Glomerular
filtration rate (GFR) and renal plasma flow rate (RPF) were then
estimated by inulin and PAH clearance, respectively. In addi-
tion, glomerular capillary hydraulic pressure (PGC) was mea-
sured in eight rats (Group 4), four rats (Group 5a), six rats
(Group Sb), four rats (Group 6a), six rats (Group 6b) and seven
rats (Group 7) with a continuous recording, servo-nulling pres-
sure system (model 4A, Instrumentation for Physiology and
Medicine, San Diego, California, USA) as previously described
[17].
Histological studies for acute nephrotic phase and chronic
glomeruloscierosis phase treatments
Light microscopic studies were performed on the autopsy
kidney specimens (16 weeks) for the acute nephrotic treatment
phase study and on the biopsy (16 weeks) and autopsy (28
weeks) kidney specimens from the same rat for the chronic
glomerulosclerosis phase study. Tissue was immersion fixed in
10% buffered formalin, routinely processed, paraffin embedded
and 4 m sections cut and stained with periodic acid-Schiff.
Histological examination was performed without knowledge of
the treatment protocol. A semiquantitative score (sclerosis
index, SI) modified from the method of Raij, Azar and Keane
was used to evaluate the degree of glomerular sclerosis [181.
Sclerosis was defined as collapse and/or obliteration of the
glomerular capillary tuft accompanied by hyalin material, in-
crease of matrix and/or adhesion of the tuft to Bowman's
capsule. On a single section of the kidney, glomerular sclerosis
was assessed by examining all glomeruli and severity of scle-
rosis for each glomerulus was graded from 0 to 4+. Early
lesions were graded from 0.25 to 1 + as follows: a 0.25+ lesion
represented adhesions of the tuft to Bowman's capsule, a 0.5+
lesion represented sclerosis of up to 10% of the glomerulus and
1 + represented sclerosis of 10 to 25% of the glomerulus, while
2+, 3+ and 4+ represented sclerosis of 25 to 50,50 to 75 and 75
to 100% of the glomerulus, respectively. A whole kidney
sclerosis index was obtained by averaging scores from all
glomeruli on one section.
The presence or absence of mesangial expansion was also
evaluated in each glomerulus on a single section, as follows: A
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Proteinuria mg/day Mesangial
8 weeks 16 weeks S.!. expansion %2 weeks
positive score was given for glomeruli with globally (>50% of
the glomerular tuft) increased mesangial area. No score was
given for glomeruli without mesangial expansion or only focally
(50% of glomerular tuft) increased mesangial area. This scor-
ing was based on the segmental mesangial expansion often seen
in normal control rat glomeruli. These data are expressed for
the whole kidney as % mesangial expansion, representing the %
of positive glomeruli per total glomeruli.
More than 25 glomeruli were analyzed in each biopsy speci-
men and a minimum of 50 glomeruli was analyzed in the
autopsied kidney.
Analytical
Urinary protein was assessed by the Coomassie brilliant blue
method [191. Plasma sodium, plasma potassium, urinary sodium
and urinary potassium were measured by flame photometry.
Plasma creatinine was measured by a "Monarch Chemistry
System" centripetal analyzer (Instrumentation Laboratory,
Inc., Milan, Italy) by the modified Jaffe reaction, alkaline
picrate without Lloyds method, and plasma triglycerides were
measured by a modification of the method of Bucolo and David
[20]. Inulin concentrations in plasma and urine were determined
by the macro anthrone method [21]. PAH concentrations in
plasma and urine were assayed by the method of Bratton and
Marshall, modified by Smith et al [22].
Statistical methods
Results are expressed as mean standard error (SE). Com-
parisons between two time periods in the same animals or
between groups paired based on renal biopsy data were made
using the paired t-test for parametric data or Wilcoxon signed-
ranks test for nonparametric data. Nonparametric data from
multiple groups were tested using the Kruskall-Wallis test
followed by Mann-Whitney U test with modification by Bon-
ferroni's method. Parametric data from multiple groups were
compared using one-way analysis of variance (ANOVA) fol-
lowed by I-test with modification by Bonferroni's method.
Results
Acute nephrotic phase
Effect of ACEI or Ang JIRA on urinary protein excretion and
morphology. Table 1 shows urinary protein excretion rate in
Groups 1 to 3. Pilot experiments showed that i.v. infusion of
PAN induced massive proteinuria within five days, which
peaked at two weeks and then normalized at eight weeks. Thus,
Baseline Hoel 40
Fig. 1. The effect of the bradykinin antagonist Hoe 140 on proteinuria
in acute phase PAN rats. The decreased proteinuria in PAN + ACEI
rats increased significantly with Hoe (I) (*P < 0.05). In contrast, Hoe
did not change proteinuria in rats treated with PAN only (0). Mean
arterial pressure did not change with Hoe 140 in PAN + ACEI rats or
PAN rats. SE is indicated by bar.
we chose two weeks after PAN to examine the proteinuria
level. PAN rats (Group 1) showed massive proteinuria (271
38 mg/day) at 2 weeks. In contrast, in ACEI-treated rats (Group
2), this early phase proteinuria was markedly attenuated (96
35 mg/day, P < 0.01 vs. Group I). However, Ang IIRA
treatment (Group 3) did not affect proteinuria (306 34 mg/day,
P < 0.01 vs. Group 2, P = NS vs. Group 1). By eight weeks
after PAN infusion, urinary protein excretion rate decreased to
almost normal levels in all three groups without significant
change by 16 weeks (Table 1). Degree of sclerosis at 16 weeks
was similar among Groups 1 to 3 (SI 0.27 0.02, 0.26 0.02
and 0.25 0.02, respectively). Further, the degree of mesangial
expansion was also similar among the three groups (30 6%, 30
4% and 34 2%, respectively). Thus, acute phase therapy
for four weeks with ACEI or Ang IIRA did not affect the
subsequent progression over the next 12 weeks of glomerular
injury. Body weights were not different among groups at
completion of studies (body wt range 289 to 345 g).
Effect of bradykinin antagonist on proteinuria in acute phase.
Differing effect of decreasing proteinuria in PAN rats by inhib-
iting Ang II action via ACEI or Ang IIRA indicated that
non-Ang II actions of ACEI modulated acute proteinuna. Since
ACEI is known to potentiate bradykinin activity, we examined
the effects of a specific bradykinin antagonist on ACEI-induced
decrease in acute phase proteinuria. Inhibition of bradykinin
activity increased urinary protein excretion on average 41
14% in each ACEI-treated rat (197 29 vs. 256 18 sg/min,
P < 0.05; Fig. 1). This effect occurred without significantly
affecting MAP, RPF and GFR (91 2 vs. 92 2 mm Hg,
1.08 0.28 vs. 1.16 0.34 and 0.21 0.04 vs. 0.25 0.05
ml/min, P = NS, ACEI baseline vs. Hoe 140, respectively).
Bradykinin antagonist did not affect urinary protein excretion in
PAN rats not treated with ACEI (296 44 vs. 274 46 p.g/min,
P = NS), nor did it affect MAP, RPF and GFR (101 5 vs. 101
6mm Hg, 1.21 0.19 vs. 1.15 0.23 and 0.32 0.04 vs. 0.38
0.06 mI/mm, P = NS, respectively).
Chronic glomeruloscierosis phase
Effect of ACEI or Ang JIRA on urinary protein excretion.
Table 2 shows urinary protein excretion in Groups 4 to 7. There
were no differences in proteinuria at 2, 8 or 16 weeks after PAN
among the groups. However, in Group 4 without treatment,
Table 1. Proteinuria and glomerulosclerosis in acute phase PAN rats
Group 1 271 38 12 2 15 3 0.27 0.02 30 6
(N= 10)
Group 2 96 35 8 1 10 2 0.26 0.02 30 4(N = 9)
Group 3 306 34 10 2 18 3 0.25 0.02 34 2(N=7)
300.
0::::
150.
II
Results are presented as mean SE. Abbreviation is: SI, sclerosis
index.
a P < 0.01 versus Group I and Group 3
540 Tanaka el a!: Angiotensin II and bradykinin in PAN
Table 2. Urinary protein excretion in chronic phase PAN rats
Proteinuna mg/day
2 weeks 8 weeks 16 weeks 28 weeks
Group4 179±22 15±3 20±5 479a(N = 10)
Group 5a 159 25 7 1 9 2 12 6(N=8)
Group5b 197±31 10±2 14±4 9±3(N=8)
Group6a 172±41 11±3 13±5 8±3
(N=7)
Group6b 215±32 10±4 19±7 9±2(N = 8)
Group 7 N/D N/D 6 1 15 2(N=7)
Results are presented as mean SE. Abbreviation is: N/D—not done.
a P < 0.05 versus Group 5a, Sb, 6a, 6b and 7
proteinuria increased significantly at 28 weeks after PAN com-
pared to the normal age-matched control rats (Group 7) (P <
0.05). In contrast, ACEI- and Ang IIRA-treated rats (Groups
5a, 5b, 6a and 6b), showed complete absence of recurrent
proteinuna (P < 0.05, compared with Group 4).
Serum and urinary electrolytes and serum triglycerides.
Plasma and urinary electrolytes and serum triglyceride values
were measured at 28 weeks after PAN injection. Rats given
ACE! or Ang IIRA had normal levels of plasma sodium and
potassium, and no change in urinary excretion of sodium and
potassium (data not shown). Thus, high dose ACEI or Ang
IIRA, as well as low dose ACEI or Ang IIRA, had no untoward
effects on these electrolyte values. Triglycerides were not
increased in PAN-treated rats at 28 weeks (range 55 3 to 68
11 mg/dl) compared to normal control Group 7 (66 9 mg/dl).
Whole kidney function studies and micropuncture. Table 3
shows results of systemic blood pressure and renal function
studies. At 16 weeks after PAN, systemic blood pressure levels
in PAN rats (Group 4) were similar to normal control (Group 7).
Systemic pressure in PAN rats at 28 weeks after PAN contin-
ued to be normal. Glomerular capillary hydraulic pressure
levels were also similar between PAN rats and normal control
rats. High dose ACEI and low and high dose Ang IIRA
decreased the systemic blood pressure and mean arterial pres-
sure below normal. High dose ACEI and Ang IIRA also
decreased the glomerular pressure below that seen in normal
rats.
There was no difference among the groups in creatinine
clearance at the onset of therapy at 16 weeks and no difference
in clearances of creatinine, inulin or PAH at 28 weeks. Body
weight gains during treatment in Groups 6a and 6b were
significantly lower than in Group 4, PAN treated rats (P <
0.05).
Glomerular morphology of biopsy (Bx) and autopsy speci-
mens. The degrees of glomerular sclerosis and mesangial ex-
pansion were not different among the groups at the onset of
therapy at 16 weeks, as dictated by the study design (SI; 0.29
0.02 in Group 4, 0.30 0.05 in Group 5a, 0.32 0.05 in Group
Sb, 0,29 0.04 in Group 6a and 0.38 0.06 in Group 6b,
respectively, P = NS; mesangial expansion; 36 6% in Group
4,37 7% in Group 5a, 40 5% in Group Sb, 39 5% in Group
6a and 46 7% in Group 6b, respectively, P = NS). Age-
matched normal control rats (Group 7) had SI 0.09 .01 and
mesangial expansion 24 2% at biopsy, with similar morphol-
ogy at autopsy at 28 weeks (SI 0.11
.01, mesangial expansion
22 3%). Figure 2A presents the percent change in SI and
mesangial expansion from biopsy to autopsy specimens in
ACEI-treated rats. In Group 4 PAN rats without treatment, the
degree of sclerosis progressed in all rats during the twelve
weeks with an average increase in SI of 69 17% from 16 to 28
weeks after PAN. In rats given ACEI, low dose ACE! attenu-
ated substantially the degree of progression of sclerosis with
average increase in SI of only 13 21% (P = NS, Bx vs.
autopsy; P < 0.05, vs. Group 4). High dose ACE! further
attenuated the progression: SI and mesangial expansion de-
creased significantly from biopsy to autopsy (SI; —30 7%, P
<0.05, Bx vs. autopsy; P < 0.01, vs. Group 4 and P < 0.05, vs.
Group Sa, mesangial expansion; —60 7%, P <0.001, Bx vs.
autopsy; P <0.05, vs. Group 4). Figure 2b shows the percent
change in SI and mesangial expansion from biopsy to autopsy
specimens in Ang IIRA-treated rats. Low dose Ang IIRA
attenuated substantially the degree of progression of sclerosis
with average change in SI of —7 16% (P NS, Bx vs.
autopsy; P < 0.05, vs. Group 4). High dose Ang IIRA further
attenuated the progression with significant decreases in SI and
mesangial expansion (SI; —41 8%,P < 0.01, Bx vs. autopsy;
P < 0.01, vs. Group 4 and P < 0.05, vs. Group 6a, mesangial
expansion; —68 5%, P < 0.002, Bx vs. autopsy; P < 0.05, vs.
Group 4). In 15 of 16 rats (94%) treated with "high dose" ACE!
or Ang IIRA, mesangial expansion and glomerulosclerosis were
decreased with less severe lesions at autopsy than at biopsy in
these same rats. Thus, high dose ACE! and Ang IIRA had
significantly greater beneficial effects on glomerulosclerosis
compared to low dose of each of the treatments.
Discussion
Proteinuria has been widely used as an index of disease
activity in a variety of renal injuries. Changes in magnitude of
proteinuria in turn have been used as a parameter which reflects
the efficacy of a variety of therapeutic interventions, including
dietary manipulations and antihypertensive medications [23,
24]. It should be noted that the specific glomerular capillary wall
structural lesions which are linked to proteinuria have not been
established [25—28], although it is assumed that this unknown
structural lesion parallels the morphologically obvious lesions,
such as glomerular sclerosis. Of interest, a previous study in a
rat model of chronic progressive glomerular sclerosis demon-
strated that the proteinuria originates primarily from glomeruli
free of sclerosis [261. Moreover, the sieving defect in these light
microscopically intact glomeruli was largely corrected when the
prevailing abnormally high intraglomerular pressure was nor-
malized by acute administration of a vasodilator [26]. Assess-
ment of the glomerular capillary pores revealed increased
number of nonselective large pores during massive proteinuria
at baseline and a reduction in these pores toward, but not to, the
normal control level by normalization of glomerular pressure.
Thus, although the precise structural abnormality of the gb-
merular capillary wall responsible for the sieving defect of
chronic glomerular diseases remains unknown, and may even
vary in different diseases, the previous studies [26—29] establish
the notion that the abnormality consists of two separate com-
ponents, one acutely reversible (or 'functional') and the other
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Table 3. Whole kidney function and glomerular capillary pressure in chronic phase PAN rats
SBP mm Hg
MAP
mm Hg
PGC
mm Hg
N
C. mi/mm C1,, CPAH
16W 28W 16W 28W mI/mm
Group 4 118 3 127 3 110 4 56 2
(8)
1.04 0.09 1.03 0.23 1.02 0.05 4.33 0.26
Group 5a 123 3 128 3 108 5 54 5
(4)
1.30 0.12 1.13 0.21 0.98 0.09 5.61 0.63
Group Sb 115 4 101 88 3C 46 l
(6)
1.08 0.13 1.37 0.27 1.09 0.11 4.58 0.45
Group 6a 122 4 100 3a,b 91 4" 49 6
(4)
1.34 0.21 1.16 0.23 1.01 0.16 4.53 0.62
Group 6b 114 3 97 4 91 Sc 45 1C
(6)
1.00 0.08 1.20 0.16 0.93 0.05 5.45 0.81
Group 7 114 2 118 4 100 4 53 3
(7)
1.11 0.06 1.25 0.13 1.03 0.07 4.68 0.42
Results are presented as mean SE. Abbreviations are: SBP, systolic blood pressure; Car, creatinine clearance; C,,,, inulin clearance; CPAH,
para-aminohippurate clearance; MAP, mean arterial pressure; P0, glomerular capillary pressure.
a P < 0.01 versus Group 4b P < 0.05 versus Group 7
c P < 0.01 versus Group 4
"P < 0.05 versus Group 4
e P < 0.05 versus Group 4
acutely nonreversible (or 'chronically fixed'). Whether these
functional and structural components are pathogenetically
linked, and attributable to Ang II per se, was investigated in
these studies.
Our results show that the acute phase therapy with either
ACEI or Ang IIRA does not affect the development of glomer-
ulosclerosis, although ACEI, in contrast to Ang IIRA, was
effective in decreasing the acute nephrotic phase proteinuria.
Although the possibility that progression of glomerulosclerosis
beyond 16 weeks might be affected differentially by these acute
treatments has not been specifically excluded, the similar injury
12 weeks after therapy suggests that subsequent progression
also will be parallel. Previous investigations, using repeated
PAN injections and/or lower doses of ACE!, showed no effect
of ACE! on massive proteinuria in the acute nephrotic stage of
PAN nephrosis [7, 30, 31]. Our pilot study confirmed that low
dose ACE! does not attenuate massive proteinuria in the acute
nephrotic stage, and contrasts the effectiveness of high dose
ACEI in reducing proteinuria. These findings together with the
salient and prompt effect of the bradykinin antagonist to
dampen the antiproteinuric effect of ACEI argues strongly that
the antiproteinuric effect of ACE! during early stage is 'func-
tional' in nature. It also supports that ACEI's ability to reduce
proteinuria at this early stage is driven by angiotensin-indepen-
dent mechanism(s). Recently, Hutchison, Webster and Jaffa
showed that ACE! decreased proteinuria and also increased
renal kallikrein mRNA in nephrotic rats with Heymann nephri-
tis [32]. Our results with the bradykinin antagonist further
indicate that ACEI's early effect on proteinuria largely reflects
its well known ability to inhibit kininase activity, thereby
augmenting the local level of bradykinin [331, although the
possibility that other vasoactive substances might contribute to
lesser degree exists. It is possible that higher doses or longer
duration of bradykinin antagonism may result in even greater
reversal of the reduced proteinuria in ACEI-treated rats.
How, then, does bradykinin lead to correction of the sieving
defect in the glomerular capillary wall in such a short period of
time? Bradykinin decreased resistances of both afferent and
efferent arterioles in an earlier study [34]. However, recent in
vitro [35] and in vivo [36] studies found that bradykinin acts as
a selective efferent arteriolar vasodilator. In rats with severe
vasoconstriction of the efferent arteriole, ACE! induced a
profound dilation of the arteriole and a marked fall in glomer-
ular pressure, phenomena readily abolished by simultaneous
administration of a specific bradykinin antagonist [36]. It is
therefore conceivable that the ACE!-activated mechanism of
bradykinin to correct the sieving defect in early proteinuria is
channeled through its ability to reduce glomerular pressure and
the stretch force imposed upon the glomerular capillary wall.
Such reduction in stretch force can reduce the number of large
non-selective pores [26, 27]. ACEI may also correct the im-
paired charge barrier function of the glomerular capillary wall
seen in PAN nephrosis [37].
In contrast to the effects seen in the early stage, ACE! and
Ang !IRA were equally effective in protecting glomeruli from
progressive glomerular sclerosis and from 'chronically fixed'
sieving defect of the glomerular capillary wall. Ang !I has
known effects on growth and matrix production in addition to
its vasoconstrictor effects [38, 39]. Previous data showed that
ACE! not only inhibits rapid maturational growth, but also
glomerulosclerosis associated with aging [40, 41]. Since mesan-
gial matrix production is a key element linked to glomeruloscle-
rosis, and angiotensin I! promotes matrix accumulation [38],
the decreased matrix in ACEI-treated rats versus age-matched
controls suggests that ACE! also inhibits the nonnal increase in
matrix seen with maturational growth and aging. Our previous
data showed for the first time the potential greater therapeutic
benefit of ACEI, in doses higher than those required for blood
pressure control, on structural injury in progressive renal
disease [1]. These same high doses were also beneficial in the
non-hypertensive PAN model in the current study. Of interest,
it has been proposed that lower than normal systemic blood
pressure can ameliorate structural injury, although a mecha-
nism for such an effect has not been clarified [42]. Recently,
Heeg et al showed that the long-term antiproteinuric effect of
ACE! is not influenced by acute changes in systemic and renal
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Fig. 2A. Percent changes of sclerosis index (•) andmesangial expansion (0) from biopsy to autopsy specimens in rats with no treatment (No
Rx) (Group 4), "low dose" ACE! (Group 5a) and "high dose" ACE! (Group 5b), and B. in rats with no treatment (no Rx) (Group 4), "low dose"
Ang JIRA (Group 6a) and "high dose" Ang IIRA (Group 6b). Each closed circle represents the percent change of sclerosis index at biopsy versus
autopsy in each rat. Each open circle represents the percent change of mesangial expansion at biopsy versus autopsy in each rat. The mean value
is indicated by bar.
hemodynamics [43]. ACEI or Ang IIRA effect in reducing the
chronic phase proteinuria therefore likely reflects at least in part
their ability to ameliorate a structural defect in the glomerulus
in the PAN model. Unlike early proteinuria, the glomerular
sclerosis and the attendant proteinuria in the chronic phase are
driven by mechanism(s) involving endogenous angiotensin II
actions. Thus, these studies show for the first time that ACEI's
functional (that is, acute effects on proteinuria) and structural
(that is, chronic effects on glomeruloscierosis) effects are
largely unrelated, the former related to bradykinin and the latter
to angiotensin H actions.
In view of these separate pathogenic mechanisms acting in
early versus late phase of the progressive chronic disease, it is
clear that the efficacy of a given experimental treatment to
protect glomeruli from glomeruloscierosis cannot be predicted
from its early effect on proteinuria. For example, a powerful
angiotensin-independent agent capable of reducing early pro-
teinuria may not protect glomeruli from (angiotensin 11-depen-
dent) glomerular sclerosis. Likewise, the potency of angioten-
sin inhibitors, like Ang IIRA, to prevent glomerular sclerosis
may be underestimated by their apparent ineffectiveness to
decrease early proteinuria soon after initiation of treatment. For
these reasons it appears imperative to firmly establish the
efficacy of ACE! in human disease based on both long-term
functional and morphological data.
Finally, we are also intrigued by the finding that amelioration
of nephrotic phase proteinuria in PAN rats by short-term ACEI
treatment alone did not affect the subsequent progressive
glomeruloscierosis (Group 2). Thus, both Ang IIRA-treated rats
with massive early proteinuna and ACEI-treated rats without
early nephrotic syndrome eventually developed similarly se-
vere glomerular sclerosis. The results suggest that proteinuna
per se has a limited role in the development of glomeruloscie-
rosis, although studies with longer duration of nephrotic pro-
teinuria are necessary.
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